comprehensive -WSS

comprehensive

author：fashion 2025-08-12 11:29:04 - browse：4

Dr. Laurie Glimcher, CEO of Dana Farber Cancer Institute, opens both arms while talking — coverage from STAT — Laurie Glimcher, CEO of Dana Farber Cancer Institute, is the architect of the biggest shakeup in Boston health care in decades. David L. Ryan/Globe Staff

Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks.

The younger Glimcher took that advice to heart. In the late 1990s at her Harvard immunology lab, Glimcher and her postdoctoral student began a series of experiments that colleagues deemed “crazy.” But after a year of trial and error, the lab had a eureka moment when it found that white blood cells could be reprogrammed, a seminal discovery that led to new ways to treat cancer.

“Most scientists do good work, but they don’t transform a scientific question,” said Glimcher. “I always felt the only way to do that is to think big and go after something that’s going to be really important.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

WSS

Eli Lilly, Pfizer, and others want in on the online prescription market

Parkinson’s finding may lead to tests and, someday, treatments

Florida officials tell state schools to teach AP Psychology 'in its entirety'

Why doctors need education on FDA device approval process

Medicare Advantage today, explained in one chart

Group behind ProMed defends move to subscription

focus

comprehensive

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA approves Sage Therapeutics’ rapid

Bright Health sells Medicare Advantage business to Molina

Physicians aren't 'burning out.' They're suffering from moral injury

How one medical school became remarkably diverse

Biotech venture capitalists face new demands from investors

As demand for Covid shots wanes, Moderna seeks its next success

eGenesis tests gene

In age of alternative facts, a scholarly course on calling out crap

Prior authorization will have to move faster under new Biden rule

leisure time

Biotech startup Celsius cuts 75% of staff ahead of first trial start

H.R. 3 is the wrong path to lower drug costs

The cancer stories no one wants to hear

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Humana cuts profit projections as Medicare Advantage costs soar

Why doctors need education on FDA device approval process

focus

Wikipedia

explore

explore